Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis.
OBJECTIVE
To investigate the effects of desferrioxamine (DFO) infusion on chronic disease anemia (CDA) of rheumatoid arthritis (RA) by evaluating interleukin-6 (IL-6) and erythropoietin (EPO) production.


METHODS
Five patients with RA and CDA (group I) were treated with DFO, 500 mg daily, through a continuous 10-h subcutaneous infusion 5 days a week for 4 weeks. One month after withdrawal, DFO was resumed in all five group I patients (group II) with an increase to 1 g daily following the previous treatment schedule. Clinical and laboratory parameters were evaluated weekly during the two study periods. Serum EPO was measured by radioimmunoassay. IL-6 was detected by the enzyme-linked immunoabsorbent assay method.


RESULTS
No significant variations in hematological parameters, IL-6 or EPO levels were observed in group I patients. After 1 week of DFO 1 g daily, reticulocyte counts and EPO improved significantly. Hemoglobin and hematocrit rose significantly after 3 weeks of 1 g daily DFO therapy. Four weeks after DFO withdrawal, EPO, reticulocyte counts, hemoglobin and hematocrit returned to baseline levels. A significant improvement in the clinical parameters of disease activity was observed, particularly in group II patients.


CONCLUSIONS
DFO improves CDA in RA patients. The beneficial effects on erythropoiesis seem to be related to improved EPO responsiveness to the anemia.
Salvarani
C
C
2Divisione di Medicina, Azienda Ospendaliera Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
Baricchi
R
R
Lasagni
D
D
Boiardi
L
L
Piccinini
R
R
Brunati
C
C
Macchioni
P
P
Portioli
I
I
D000740:Anemia / Q000188:drug therapy* / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000150:complications* / Q000652:urine; D002908:Chronic Disease; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D004921:Erythropoietin / Q000096:biosynthesis; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D015850:Interleukin-6 / Q000096:biosynthesis; D007501:Iron / Q000652:urine; D008297:Male; D008875:Middle Aged; D017262:Siderophores / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D015850:Interleukin-6; D017262:Siderophores; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine